Nitrolingual Akut (Glyceryl Trinitrate)

Glyceryl trinitrate is converted to nitric oxide after administration. Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle. This cascade causes relaxation of coronary and peripheral arteries, lowering myocardial oxygen demand and improving blood flow during an angina attack.

The dosage of Nitrolingual Akut is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and response to therapy. Healthcare professionals adjust the number of sprays and frequency according to individual needs and clinical guidelines.

Safety data for glyceryl trinitrate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Nitrolingual Akut, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nitrolingual Akut delivers glyceryl trinitrate via an oromucosal spray, offering rapid onset of action compared with oral tablets. Unlike longer‑acting nitrate preparations, the spray is intended for immediate relief of acute attacks and can be used without the need for sublingual tablets, providing a convenient alternative for quick symptom control.

Nitrolingual Akut should be stored at room temperature, below 25 °C, in its original packaging. Keep the spray away from moisture, direct sunlight, and extreme temperatures to maintain potency and ensure the device functions correctly.

The product is an oromucosal spray. The patient places the nozzle inside the mouth, typically under the tongue or against the inner cheek, and actuates the device to deliver a measured dose. The spray is absorbed through the oral mucosa, providing rapid systemic exposure.

The most serious risks include severe hypotension, which can lead to fainting or shock, and rare cases of methemoglobinemia or allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive blood‑pressure drop and seek immediate medical attention if serious symptoms develop.

Nitrolingual Akut is contraindicated in individuals with known hypersensitivity to glyceryl trinitrate or any nitrate, and in patients who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours due to the risk of dangerous blood‑pressure reductions. Clinicians should also exercise caution in patients with severe anemia or recent head injury.